<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789111</url>
  </required_header>
  <id_info>
    <org_study_id>18781</org_study_id>
    <nct_id>NCT02789111</nct_id>
  </id_info>
  <brief_title>Trial of Alvimopan in Major Spine Surgery</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Trial of Alvimopan in Major Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigator has chosen to study the reconstructive spinal surgery patient population
      because it is believed that the use of alvimopan in these patients at the University of
      Virginia will give the scientific community significant insight into the broader
      applicability of this drug into other surgical populations, the impact of this drug on the
      perception of pain (as opposed to simply the consumption of opioids), and its impact on total
      hospital charges, resource utilization, and functional outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain control following major spine surgery is difficult to achieve. Opiates are often
      necessary in high doses, and may be associated with significant side effects. Such side
      effects may include urinary retention, altered mental status, depressed respiratory drive,
      and constipation, and may lead to reduced nutritional intake in the postoperative period.
      Importantly, post-operative nutrition may impact the incidence of complications following
      spine surgery.1 Alvimopan is a peripheral-acting opiate antagonist designed to decrease the
      gastrointestinal complications of perioperative systemic opioid administration.

      Pain control following major spine surgery is difficult to achieve. Opiates are often
      necessary in high doses, and may be associated with significant side effects including
      constipation. Alvimopan is a drug approved by the Food and Drug Administration (FDA) and is
      used to help the bowel recover more quickly in patients who are having bowel surgery, so that
      they can eat solid foods and have regular bowel movements. Alvimopan is in a class of
      medications called peripherally acting mu-opioid receptor antagonists. It works by protecting
      the bowel from the constipation effects of opioid (narcotic) medications that are used to
      treat pain after surgery.

      The purpose of this study is to determine if the use of alvimopan in major spine surgery
      reduces the time to first bowel movement. By assessing the use of alvimopan in reconstructive
      spinal surgery patients, researchers hope to give the scientific community insight into the
      broader use of this drug in other surgical populations, as well as gathering information on
      the impact of hospital charges and overall post-operative patient satisfaction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to first bowel movement</measure>
    <time_frame>Time to event( up to 7 days); From date of day of surgery until the date of first documented bowel movement</time_frame>
    <description>time to first bowel movement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to resumption of PO intake</measure>
    <time_frame>time to event ( up to 7 days); From date of day of surgery until the date of first documented PO intake</time_frame>
    <description>time to resumption of PO intake</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Alvimopan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 mg alvimopan twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvimopan</intervention_name>
    <description>Alviimopan 12 mg twice daily up to 15 doses</description>
    <arm_group_label>Alvimopan</arm_group_label>
    <other_name>Entereg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily up to 15 doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major spine surgery scheduled as part of clinical care

          -  18-80 years

        Exclusion Criteria:

          -  More than three doses of any opioid within one week of surgery

          -  Pregnancy

          -  Prisoners

          -  Unable to provide consent

          -  Emergency surgery

          -  Chronic kidney disease stage 5 (GFR &lt; 15 ml/min)

          -  Severe hepatic impairment

          -  Recent myocardial infarction (within the last 3 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhiken Naik, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesiology Attending</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcia E Birk, RN</last_name>
    <phone>434-924-2283</phone>
    <email>meb2w@virginnia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia E Birk, RN</last_name>
      <phone>434-924-2283</phone>
      <email>meb2w@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bhiken Naik, MBBCh</last_name>
      <phone>434-924-2283</phone>
      <email>bin4n@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bhiken Naik, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stambough JL, Beringer D. Postoperative wound infections complicating adult spine surgery. J Spinal Disord. 1992 Sep;5(3):277-85.</citation>
    <PMID>1520986</PMID>
  </reference>
  <reference>
    <citation>Crawford MW, Hickey C, Zaarour C, Howard A, Naser B. Development of acute opioid tolerance during infusion of remifentanil for pediatric scoliosis surgery. Anesth Analg. 2006 Jun;102(6):1662-7.</citation>
    <PMID>16717305</PMID>
  </reference>
  <reference>
    <citation>Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, Fletcher D, Chauvin M. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000 Aug;93(2):409-17.</citation>
    <PMID>10910490</PMID>
  </reference>
  <reference>
    <citation>Rauf K, Vohra A, Fernandez-Jimenez P, O'Keeffe N, Forrest M. Remifentanil infusion in association with fentanyl-propofol anaesthesia in patients undergoing cardiac surgery: effects on morphine requirement and postoperative analgesia. Br J Anaesth. 2005 Nov;95(5):611-5. Epub 2005 Sep 9.</citation>
    <PMID>16155034</PMID>
  </reference>
  <reference>
    <citation>Cortínez LI, Brandes V, Muñoz HR, Guerrero ME, Mur M. No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia. Br J Anaesth. 2001 Dec;87(6):866-9.</citation>
    <PMID>11878688</PMID>
  </reference>
  <reference>
    <citation>Fletcher D, Pinaud M, Scherpereel P, Clyti N, Chauvin M. The efficacy of intravenous 0.15 versus 0.25 mg/kg intraoperative morphine for immediate postoperative analgesia after remifentanil-based anesthesia for major surgery. Anesth Analg. 2000 Mar;90(3):666-71.</citation>
    <PMID>10702454</PMID>
  </reference>
  <reference>
    <citation>Lee LH, Irwin MG, Lui SK. Intraoperative remifentanil infusion does not increase postoperative opioid consumption compared with 70% nitrous oxide. Anesthesiology. 2005 Feb;102(2):398-402.</citation>
    <PMID>15681957</PMID>
  </reference>
  <reference>
    <citation>Bell TJ, Poston SA, Kraft MD, Senagore AJ, Delaney CP, Techner L. Economic analysis of alvimopan in North American Phase III efficacy trials. Am J Health Syst Pharm. 2009 Aug 1;66(15):1362-8. doi: 10.2146/ajhp080329.</citation>
    <PMID>19635772</PMID>
  </reference>
  <reference>
    <citation>Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, Du W, Schmidt WK, Wallin BA; Alvimopan Postoperative Ileus Study Group. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005 Jun;48(6):1114-25; discussion 1125-6; author reply 1127-9.</citation>
    <PMID>15906123</PMID>
  </reference>
  <reference>
    <citation>Ludwig K, Enker WE, Delaney CP, Wolff BG, Du W, Fort JG, Cherubini M, Cucinotta J, Techner L. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg. 2008 Nov;143(11):1098-105. doi: 10.1001/archsurg.143.11.1098.</citation>
    <PMID>19015469</PMID>
  </reference>
  <reference>
    <citation>Viscusi ER, Goldstein S, Witkowski T, Andonakakis A, Jan R, Gabriel K, Du W, Techner L, Wallin B. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc. 2006 Jan;20(1):64-70. Epub 2005 Dec 7. Erratum in: Surg Endosc. 2006 Mar;20(3):537.</citation>
    <PMID>16333556</PMID>
  </reference>
  <reference>
    <citation>Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, Wallin BA; Alvimopan Postoperative Ileus Study Group. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004 Oct;240(4):728-34; discussion 734-5.</citation>
    <PMID>15383800</PMID>
  </reference>
  <reference>
    <citation>Herzog TJ, Coleman RL, Guerrieri JP Jr, Gabriel K, Du W, Techner L, Fort JG, Wallin B. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol. 2006 Aug;195(2):445-53. Epub 2006 Apr 19.</citation>
    <PMID>16626607</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Bhiken I. Naik, MD</investigator_full_name>
    <investigator_title>Anesthesiology attending</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alvimopan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

